丹纳赫Q4业绩超预期，2026年核心收入增长目标3%-6%

Core Insights - Danaher Corporation (DHR.N) plans to release its Q4 and full-year 2025 financial results in late February 2026, with management having already disclosed that Q4 performance exceeded expectations during the JPM 2026 conference [1] - The company has set a target for core revenue growth of 3% to 6% for the fiscal year 2026, indicating a focus on recovery in the life sciences market and the Chinese diagnostics market [2] Financial Performance - For Q4 2025, Danaher reported revenue of $6.838 billion, a year-over-year increase of 4.5% (core growth of 2.5%), and adjusted EPS of $2.23, up 4% [2] - The biotechnology segment grew by 8.8%, while the life sciences and diagnostics segments saw growth of 2.6% and 3.1%, respectively [2] Stock Performance - As of February 12, 2026, Danaher's stock closed at $215.27, down 2.14% for the day, with an intraday low of $208.55, reflecting a daily volatility of 5.02% [3] - Over the past five days, the stock has seen a cumulative decline of 0.22%, with a total price fluctuation of 5.68% [3] Institutional Views - A positive outlook is maintained by institutions, with 89% of 28 institutions rating Danaher as "buy" or "hold," and an average target price of $264.18, with a high of $310 [4] - Institutions are focusing on the company's acquisition discipline and the potential for market recovery, while not adjusting short-term ratings [4]